No big deals for Gilead, analyst says; Merck has to fight Vioxx investor claims; LA sues AstraZeneca over Toprol XL;

@FiercePharma: Paul Allen Just Got One Step Closer To Mapping The Human Brain. More from Forbes | Follow @FiercePharma

@EricPFierce: Will Sun's Shanghvi use his top dog standing to influence other Indian drugmakers to step up their game? Check out the feature from FierceBiotech | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Contrave controversy puts Orexigen, Takeda in unwelcome spotlight. Article | Follow @CarlyHFierce

> Don't expect any mega-size buyouts from Gilead Sciences ($GILD), analysts say, expecting the California-based biotech to stick to pipeline-building deals. Report

> Merck & Co. ($MRK) has to fight investor claims that it concealed the risks of its now-withdrawn painkiller Vioxx. Report

> Louisiana Attorney General Buddy Caldwell sued AstraZeneca ($AZN), claiming the company used "baseless patent infringement lawsuits" and other techniques to keep its monopoly on the cardiovascular drug Toprol XL. Report

> Japanese drugmaker Daiichi Sankyo says it plans to buy back up to 3.98% of its own shares. Report

> Slovenia-based Krka posted a 30% hike in first-quarter profits, thanks to the strengthening Russian rouble; sales in Russia fell in euro terms. Report

> FedEx ($FDX) wants credit for helping law enforcement crack down on illegal online pharmacies. Report

> A bill allowing biosimilar substitution, with doctor notification, advanced in the New Jersey Assembly. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Glaucoma micro stent player Glaukos files to raise up to $86M in an IPO. Article | Follow @FierceMedDev

@VarunSaxena2: Philips quality improvement plan hit by recall at its troubled Cleveland facility. Report | Follow @VarunSaxena2

@EmilyWFierce: Which global markets should drugmakers target? China, yes--but old European standbys, too. More from FiercePharma | Follow @EmilyWFierce

> Medtronic's vein closure device recalled in Europe, Asia right around time of its U.S. launch. More

> FDA clears BD insulin infusion pump designed with diabetes patient advocacy groups. Article

Biotech News

@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Talked to two of the founders at Denali, which just drew a $217M round for neurodegeneration R&D. More | Follow @JohnCFierce

> Eli Lilly to work with Sanford-Burnham on autoimmune diseases. Item

> MPM rounds up $400M for biotech VC with Novartis and Astellas on board. Story

> Sage steps up to a pivotal PhIII as brain seizure drug aces trial challenge. Article

Pharma Manufacturing News

> Troubled Wockhardt recalls blood pressure med in U.S. Story

> Romark recalls pediatric diarrhea treatment Alina. News

> Sun and Ranbaxy marriage puts Sun founder Shanghvi in position to influence industry. Item

> Danaher, drawn by Pall's biopharma biz, will pay $13.8B for filtration specialist. Article

> Perrigo buys Patheon's softgel operations in Mexico. Report

Pharma Asia News

> Japan's MHLW sets Sovaldi price, hep C competition heats up. More

> Ranbaxy faces U.S. racketeering suit for blocking launch of Roche, Novartis generics. Story

> India's Lupin buys Brazil's Medquimica as part of M&A growth plan. Report

> Australia budget promises more digging on reimbursement, fees. Item

> Japan readies to sign new IP law it sees as win-win. Article

Vaccines News

> NewLink continues cancer vaccine Ph III trial with interim data under wraps. Story

> BiondVax rounds up $9.5M in IPO. Item

> Bavarian Nordic smallpox vaccine scores two late-stage trial wins. Article

> NIH-backed West Nile candidate enters PhI trials at Duke. Story

> Nima Farzan takes over as PaxVax CEO. Report

CRO News

> QPS cuts the ribbon on a new lab for early-stage R&D. News

> Theorem expands in Europe with new supplies facility. More

> Evotec brightens its outlook after $286M Sanofi deal. Report

> Patheon sells off its Mexican division for $34M. Item

> WuXi weighs going private with a deal on the table. Article

And Finally... CVS ($CVS) agreed to pay $22 million to resolve a federal investigation into painkiller sales in Florida. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.